Reincarnation of bacteriocins From the Lactobacillus pangenomic graveyard by Collins, Fergus W. J. et al.
UCC Library and UCC researchers have made this item openly available. Please let us know how
this has helped you. Thanks!
Title Reincarnation of bacteriocins From the Lactobacillus pangenomic
graveyard
Author(s) Collins, Fergus W. J.; Mesa-Pereira, Beatriz; O'Connor, Paula M.; Rea,
Mary C.; Hill, Colin; Ross, R. Paul
Publication date 2018
Original citation Collins, F. W. J., Mesa-Pereira, B., O'Connor, P. M., Rea, M. C., Hill, C.
and Ross, R. P. (2018) 'Reincarnation of Bacteriocins From the
Lactobacillus Pangenomic Graveyard', Frontiers in Microbiology, 9,
1298 (9pp). doi: 10.3389/fmicb.2018.01298
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://www.frontiersin.org/articles/10.3389/fmicb.2018.01298/full
http://dx.doi.org/10.3389/fmicb.2018.01298
Access to the full text of the published version may require a
subscription.
Rights © 2018, Collins, Mesa Pereira, O'Connor, Rea, Hill and Ross. This is
an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original
author(s) and the copyright owner are credited and that the original
publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
https://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/6675
Downloaded on 2019-04-19T20:32:10Z
ORIGINAL RESEARCH
published: 02 July 2018
doi: 10.3389/fmicb.2018.01298
Frontiers in Microbiology | www.frontiersin.org 1 July 2018 | Volume 9 | Article 1298
Edited by:
Octavio Luiz Franco,
Universidade Católica de Brasília,
Brazil
Reviewed by:
Jens Kreth,
Oregon Health & Science University,
United States
Zhoujie Xie,
Tianjin University of Science and
Technology, China
*Correspondence:
R. Paul Ross
p.ross@ucc.ie
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 17 April 2018
Accepted: 28 May 2018
Published: 02 July 2018
Citation:
Collins FWJ, Mesa-Pereira B,
O’Connor PM, Rea MC, Hill C and
Ross RP (2018) Reincarnation of
Bacteriocins From the Lactobacillus
Pangenomic Graveyard.
Front. Microbiol. 9:1298.
doi: 10.3389/fmicb.2018.01298
Reincarnation of Bacteriocins From
the Lactobacillus Pangenomic
Graveyard
Fergus W. J. Collins 1,2,3, Beatriz Mesa-Pereira 1,2, Paula M. O’Connor 1,2, Mary C. Rea 1,2,
Colin Hill 2,3 and R. Paul Ross 1,2,3*
1 Teagasc Food Research Centre, Cork, Ireland, 2 APC Microbiome Ireland, University College Cork, Cork, Ireland,
3Department of Microbiology, University College Cork, Cork, Ireland
Bacteria commonly produce narrow spectrum bacteriocins as a means of inhibiting
closely related species competing for similar resources in an environment. The increasing
availability of genomic data means that it is becoming easier to identify bacteriocins
encoded within genomes. Often, however, the presence of bacteriocin genes in a
strain does not always translate into biological antimicrobial activity. For example, when
analysing the Lactobacillus pangenome we identified strains encoding ten pediocin-like
bacteriocin structural genes which failed to display inhibitory activity. Nine of these
bacteriocins were novel whilst one was identified as the previously characterized
bacteriocin “penocin A.” The composition of these bacteriocin operons varied between
strains, often with key components missing which are required for bacteriocin production,
such as dedicated bacteriocin transporters and accessory proteins. In an effort to
functionally express these bacteriocins, the structural genes for the ten pediocin
homologs were cloned alongside the dedicated pediocin PA-1 transporter in both
Escherichia coli and Lactobacillus paracasei heterologous hosts. Each bacteriocin was
cloned with its native leader sequence and as a fusion protein with the pediocin
PA-1 leader sequence. Several of these bacteriocins displayed a broader spectrum of
inhibition than the original pediocin PA-1. We show how potentially valuable bacteriocins
can easily be “reincarnated” from in silico data and produced in vitro despite often
lacking the necessary accompanying machinery. Moreover, the study demonstrates how
genomic datasets such as the Lactobacilus pangenome harbor a potential “arsenal”
of antimicrobial activity with the possibility of being activated when expressed in more
genetically amenable hosts.
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INTRODUCTION
Bacteria exist in complex communities, under constant competition from other strains and species
for nutrients and space. The production of antimicrobial peptides known as bacteriocins has been
shown to be one means by which such strains can gain a competitive advantage (Kommineni et al.,
2015). Bacteriocins can be broad spectrum, inhibiting a variety of bacteria, or narrow spectrum
where they inhibit primarily closely related species. As closely related species are more likely
to occupy the same environmental niche as the producer, these bacteriocin genes could offer a
potentially useful armory of antimicrobials in helping the producer establish itself in such a niche.
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The increasing availability of genomic data has changed
the way we identify and study bacteriocins in communities.
Bioinformatic screening tools such as BAGEL (de Jong et al.,
2010) and antiSMASH (Weber et al., 2015) can now process
vast amounts of genomic data to search for antimicrobial
operons and genes (Letzel et al., 2014; Walsh et al., 2015). This
allows us to identify previously uncharacterized bacteriocins
and antibiotics, and to understand the extent of which strains
encode these natural weapons for targeting competitors. In
many of these cases however, the bacteriocin genes appear to
be inactive antimicrobial relics which are unlikely to play an
active role, given the degradation of the surrounding accessory
genes. Mutations within genes, loss of key genes within operons
and tight transcriptional regulation can all prevent cells from
producing these antimicrobials. This means that many such
strains harbor potentially useful bacteriocins that are destined
to remain uncharacterized due to a lack of in vitro production.
One method to overcome this issue is to clone the antimicrobial
operon into a host where expression can be controlled. This
allows for the natural bacteriocin regulation to be circumvented
and/or gene loss to be overcome, thus ensuring production of
otherwise unavailable antimicrobials for further characterization
and potential exploitation.
In this study we focused on the expression of potential
class IIa bacteriocins from members of the Lactobacillus Genus
Complex. Bacteriocins are divided into different classes based
on their modifications, structure and mode of action. Class
II bacteriocins are not subject to extensive post-translational
modification and the class IIa bacteriocins are single peptides
with a highly conserved “YGNGV” N-terminal sequence. These
bacteriocins (also known as “pediocin-like” bacteriocins) are
relatively narrow spectrum and display high levels of activity
against Listeria species (Cotter et al., 2005). They bind to
the mannose phosphotransferase transport system in sensitive
strains and subsequently induce pore formation which leads
to cell death (Zhou et al., 2016). The effective production of
these bacteriocins depends on the production of several other
associated proteins (Fimland et al., 2005). For example, an
associated ABC transporter must be produced by cells in order
to transport the bacteriocin outside the cell, and an immunity
protein is also required to protect the producing strain from
being killed by its own bacteriocin (Drider et al., 2006). Certain
class IIa bacteriocins also require an accessory protein for
correct disulphide bond formation (Oppegård et al., 2015). These
operons may also have a three-component regulatory system
which regulates expression of the bacteriocin. Here, when the
concentration of an inducer peptide encoded within the operon
reaches a certain level it signals a transmembrane histidine kinase
which in turn activates a response regulator which initiates
transcription of the bacteriocin operon (Ennahar et al., 2000).
The Lactobacillus Complex analyzed in this study
encompasses the Lactobacillus, Pediococcus, Leuconostoc,
Weissella, Fructobacillus, and Oenococcus genera and numerous
pediocin-like bacteriocins have been associated with this
grouping (Collins et al., 2017). Previously Sun et al. (2015)
sequenced the genomes of 213 strains belonging to this complex,
these were then subject to both in silico and in vitro bacteriocin
screening (Collins et al., 2017). Numerous strains from that study
were found to encode bacteriocin operons but did not show
in vitro bacteriocin production. Several of these strains encoded
complete operons for pediocin-like bacteriocins, whilst more
had incomplete operons harboring just structural and immunity
genes. Whereas regulatory issues may prevent expression of
bacteriocins in strains harboring complete operons, those
without the necessary transporter systems seem unlikely to be
produced. It is unclear as to why such strains encode intact
bacteriocin and immunity genes whilst lacking the machinery
needed to actually produce and secrete these antimicrobials.
One potential explanation for this is that these strains may
have maintained the bacteriocin immunity gene under selective
pressure from these antimicrobials. The neighboring bacteriocin
encoding gene is small and may have simply been maintained
due its proximity to the immunity gene, the much larger
transport machinery may then have been lost.
In this study we use an expression systems derived by Mesa-
Pereira et al. (2017) to reincarnate these bacteriocins, allowing
for in vitro production. It was found that for production of
pediocin PA-1, only the structural gene and the transporter
were necessary for bacteriocin production and secretion. As
some of our putative novel bacteriocins lacked an associated
transporter, the pediocin PA-1 transporter was used in each case.
Bacteriocin peptides were detected by mass spectrometry and
activity was identified by screening against a range of indicator
organisms. The systems used have allowed us to isolate seven
novel bacteriocins and represents a unique and rapid way of
producing bacteriocins. This method allows us to reincarnate
otherwise ineffectual antimicrobial relics identified solely by
in silicomethods.
MATERIALS AND METHODS
Strains and Culture Conditions
Bacterial strains and growth conditions used are displayed in
Supplementary Table 2. E. coli HST08 StellarTM cells (Takara
BIO USA, Inc., Mountain View, CA) were used for normal
cloning methods, E. coli BL21 TunerTM (DE3) cells (Novagen,
EMD Millipore, Billerica, MA) were used for expression of
the transformed genes. E. coli strains were grown in Luria-
Bertani (LB)media containing 50µg/ml of ampicillin for plasmid
selection. IPTG (Isopropyl β-D-1-thiogalactopyranoside) (Fisher
Scientific, Dublin, Ireland) was added to the growth media to
induce gene expression. L-(+)-arabinose and D -(+)-glucose
(Sigma Aldrich, Arklow, Ireland) were also added to the media
to control plasmid levels in recombinant cells. L. paracasei
NFBC338 cells were grown in modified MRS media containing
0.05% cysteine and 10µg/ml chloramphenicol (Sigma Aldrich,
Arklow, Ireland).
Molecular Cloning and Gene Expression
Total genomic DNA was extracted from the bacteriocin
encoding strains using the GenElute Bacterial Genomic DNA
Kit (Sigma Aldrich, Arklow, Ireland). Primers were designed
for amplification of the bacteriocins and transporter genes as
outlined in the In-Fusion HD cloning protocol (Takara BIOUSA,
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Inc., Mountain View, CA). For amplification of genes containing
the bacteriocin along with the native leader sequence, the genes
were amplified by PCR from the original genomic DNA of the
host strain using CloneAmp Hifi PCR premix (Takara BIO USA,
Inc., Mountain View, CA). Recursive PCR was used for the
synthesis of fusion genes containing the pediocin PA-1 leader
sequence joined to the bacteriocin structural gene (Prodromou
and Pearl, 1992). In both cases, the fragment containing the
transporter encoded gene (pedD) was amplified using pMPB1
pedD Fw1 and pMPB1 pedD Rv1 using P. acidilactici LMG2351
as a DNA template. The oligonucleotides used in this study are
listed in Supplementary Table 3. PCR products were purified
using the Illustra GFX PCR DNA and Gel Band Purificatoin kit
(GE Healthcare, UK), these were then inserted into the linearized
SphI and AvrII pMPB1 vector using In-Fusion HD cloning Plus.
pMPB1 vector is based on the commercial plasmid pETcocoTM-
2 which allows a dual control of expression; at transcriptional
level by IPTG induction and for amplification at the DNA level
replication by L-arabinose (Sektas and Szybalski, 2002).
The constructions were transformed into StellarTM competent
cells and colonies were selected on LB agar plates containing
50µg/ml of ampicillin and 0.2% D-glucose. The transformants
were confirmed by colony PCR reactions. L-arabinose was used
to increase the plasmid copy number in cells and plasmid
DNA was isolated using the NucleoSpin plasmid kit (Macherey-
Nagel, Duren, Germany) to be analyzed subsequently by double
digestion and sequencing. For bacteriocin expression, TunerTM
(DE3) E. coli cells were transformed with the bacteriocin
encoding vectors of interest. The transformants were then grown
in LB containing 50µg/ml of ampicillin and 0.2% glucose which
maintains the plasmid in a single copy state. Once cells had grown
to an OD600 of 0.5–0.7, IPTG was added at a concentration of
50µM to induce expression of the bacteriocin genes.
For expression in L. paracasei NFBC338 the pNZ44 plasmid
was used which contains the p44 constitutive promoter. Each
bacteriocin was cloned containing the pediocin promoter and
the pedD transporter, PCR fragments were amplified from
positive StellarTM transformants using the pNZ44 pedA FW
and pNZ44 pedD RV oligonucleotides. These were inserted
into the linearized NcoI-HindIII pNZ44 vector using In-
Fusion HD cloning Plus. Constructions were cloned into
StellarTM competent cells and confirmed as before. For
expression, L. paracasei NFBC338 cells were transformed
with the bacteriocin-containing plasmids by electroporation.
Transformants were grown overnight in MRS containing 0.05%
cysteine and 10µg/ml of chloramphenicol.
Bacteriocin Assays
Bacteriocin activity was determined using well diffusion assays
(WDAs). For TunerTM (DE3) E. coli transformants both
the cell supernatant and the cell lysates were analyzed for
antimicrobial activity, whilst only the supernatants were analyzed
for L. paracasei NFBC338 cells. Supernatant was isolated by
centrifugation of the liquid cultures at 4000 RCF for 15min,
these supernatants were then filtered using 0.20µm membrane
filters. For cell lysates, cell pellets were resuspended in 5ml of
phosphate-buffered saline (PBS), cells were lysed by sonication
using a MSE Soniprep 150 (MSE, London, UK). Lysates were
subsequently centrifuged at 4000 RCF for 15min and the
resulting supernatants were filtered using 0.20µm membrane
filters. For the indicator plates, 50µl of an overnight culture
of the indicator strain was added to the appropriate media
containing 1% agar. Plates were cooled and 7mm wells were
bored in the agar. 50µl of the cell supernatants/lysates being
tested were added to each well and plates were refrigerated for
2 h prior to incubation under the appropriate conditions. WDAs
were carried out in triplicate for each bacteriocin.
Bacteriocin Purification and Mass
Spectrometry
Purification and analysis was carried out for bacteriocins
encoding the pediocin PA-1 leader sequence from TunerTM
(DE3) E. coli transformants. 85ml of each culture supernatant
was applied to 2ml SP sepharose columns (GE Healthcare, UK)
pre-equilibrated with 25ml 20mM potassium phosphate buffer
25% acetonitrile, pH 2.5. Columns were washed with 20ml
20mM potassium phosphate buffer 25% acetonitrile, pH 2.5, the
bacteriocins analyzed eluted from columns with 25ml 20mM
potassium phosphate buffer 25% acetonitrile containing 2MKCl,
pH 2.5. Eluents were passed through a 6ml, 500mg Strata–E C18
SPE column pre-equilibrated (Phenomenex, Cheshire, UK) with
methanol and water. The column was washed with 6ml 30%
ethanol and then 6ml 70% 2-propanol 0.1 TFA (IPA). MALDI
TOF colony mass spectroscopy was carried out on the eluents
using an An Axima TOF2plus MALDI TOF mass spectrometer
(Shimadzu Biotech, Manchester, UK) in positive-ion reflectron
mode.
RESULTS
Identification of “Silent” Pediocin
Homologs
Previous work performed by our group analyzed bacteriocin
production in 213 Lactobacillus and related species (Collins
et al., 2017). In silico screening identified the presence of
bacteriocin operons (or remnants of operons) encoded within
the genome of a large number of these strains. Strains encoding
bacteriocins were then tested for in vitro bacteriocin production
but several strains failed to display antimicrobial activity (Sun
et al., 2015; Collins et al., 2017). This study focused on the class
IIa bacteriocins; eight strains were found to encode ten of these
pediocin-like bacteriocins but failed to display any antimicrobial
production. Of these ten potential bacteriocins identified, nine
were novel and one was identified as penocin A, a bacteriocin
previously characterized from P. pentosaceus ATCC 25745 (Diep
et al., 2006; Table 1).
Typically at least four genes are commonly required for
the production of a class II bacteriocin; a structural gene, a
transporter, an immunity gene and a gene encoding an accessory
protein (Drider et al., 2006). The operons for the ten “silent”
class IIa bacteriocins differed in their composition, with several
lacking the genes for some of the necessary bacteriocin associated
components (Figure 1). Each of these nine novel bacteriocins
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were named based on the species which produced them; e.g.,
ruminicin produced by L. ruminus. Of the operons identified,
only those encoding hordeiocin and ruminicin were found to
encode all four key components for bacteriocin production. The
acidicin operon also appeared to be complete as the structural
peptide doesn’t contain any cysteine residues for disulphide bond
formation, thus the accessory protein is probably unnecessary.
The futcin operon was the only other such operon which encoded
an ABC transporter for bacteriocin transport and leader cleavage.
The remaining operons were composed of two to three genes
encoding just the structural gene and immunity protein, with the
agilicin operon also encoding an accessory protein.
Heterologous Cloning
As there was no identifiable bacteriocin production from these
eight strains, it was decided to express these novel bacteriocins
first in an E. coli host. A modified pETcocoTM-2 vector, pMPB1,
generated by Mesa-Pereira et al. (2017) was used for bacteriocin
expression. It was previously found that only the structural gene
and the ABC transporter are required to express pediocin PA-
1 using this system. As over half of the bacteriocins identified
here lack an associated ABC transporter, the pediocin PA-1
transporter PedD was used for the expression of each of these
bacteriocins. PedD contains an intrinsic domain for cleavage of
the bacteriocin leader sequence, and as these transporters rely
on this leader sequence for peptide processing each of these
bacteriocins were cloned separately using both their native leader
sequence and as a fusion protein containing the pediocin PA-1
leader. Recursive PCR was used to generate the genes for each of
these fusion proteins; genes for the natural bacteriocins and the
PedD transporter were amplified by PCR (Prodromou and Pearl,
1992). An In-Fusion reaction was then used to assemble and join
these PCR products to the enzyme-digested pMPB1 vector. For
production in L. paracasei NFBC338, a pNZ44-derived vector
was used; in this case the bacteriocin was cloned as a fusion
with the pediocin leader along with the PedD transporter. PCR
products for these reactions were obtained using positive pMPB1
plasmids as a template. In-Fusion reaction was then used to
assemble and join these PCR products to the enzyme-digested
pNZ44 vector. The vectors used are shown in Supplementary
Table 1.
Production
E. coli TunerTM (DE3) cells transformed with the newly
constructed plasmids were grown in LB supplemented with
glucose to maintain a low-copy number and bacteriocin
expression was induced by co-incubation of the clones with
50µM IPTG for 3 h. WDAs were used to identify bacteriocin
activity from the bacterial supernatants and cell lysates.
Bacteriocins were exclusively found in the bacterial supernatant.
Antimicrobial activity was lower in cases where the native leader
of the bacteriocin sequence was used; with only four of the nine
strains displaying zones of inhibition against a sensitive indicator
(pediocin 20336a has an identical leader to pediocin PA-1). For
expression in L. paracasei NFBC338, cells were transformed by
electroporation with the bacteriocin-containing pNZ44 vectors.
Positive transformants were grown overnight and the neutralized
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FIGURE 1 | Class IIa Bacteriocin Operons.
cell free supernatant was used to identify bacteriocin production
in WDAs.
Of the bacteriocins expressed with the pediocin PA-1 leader
sequence in E. coli, 8 of the ten displayed anti-microbial activity
from the cellular supernatant against at least one indicator
organism (Table 2). Purification of the bacteriocin peptides
from the E. coli bacterial supernatant and MALDI-TOF mass
spectrometry were used to determine the mass of the active
peptides. These masses correlated closely with the predicted mass
of the bacteriocin structural peptide, allowing us to identify the
bacteriocin produced. This approach confirmed the production
of nine of the ten bacteriocins, aquaticin was not identified using
these methods, potentially due to low levels of production by
the cells (Supplementary Figure 1). The percentage amino acid
identity of these bacteriocins in comparison to pediocin ranges
from 29.5% to 93.2%. Production levels of bacteriocins were
shown to vary between the E. coli and L. paracasei expression
systems. E. coli transformants actually displayed greater or equal
bacteriocin activity compared to those produced by L. paracasei
(Table 3). The only exceptions were the original pediocin PA-1
which was used as a control and rennicin B which was produced
in very low quantities by the E. coli producer where production
was only noted after purification of the bacteriocin from the
cellular supernatant. Interestingly, L. paracasei NFBC338 failed
to produce futcin which was produced by E. coli.
Spectrum of Activity
The spectrum of activity was determined using WDAs
against 32 indicator strains for bacteriocins produced by
the E. coli transformants encoding the pediocin leader
(Table 2). Despite being of the same class of bacteriocins,
these novel antimicrobials display a varying spectrum of activity.
Interestingly, pediocin 20336a and hordeiocin inhibited the
growth of a larger number of the indicators tested than pediocin
PA-1. Aquaticin and rennicin B failed to display antimicrobial
activity in the crude supernatant from the E. coli heterologous
host, whilst acidicin displayed activity exclusively against
L. mali in this assay. Many of these bacteriocins, however, can
inhibit a wide range of Gram positive bacteria including potential
pathogens such as Enterococcus faecalis. As with most class IIa
bacteriocins, these also display potent anti-listerial activity.
Interestingly, L. mali appears to also be an extremely sensitive
indicator for testing the activity of class IIa bacteriocins here and
may prove a safer alternative over the use of Listeria strains to
test the activity of these bacteriocins.
Bacteriocin Structures
Class IIa bacteriocins tend to have a relatively conserved
structure. However, some of these novel bacteriocins display
key differences in the typical conserved regions associated with
previously characterized class IIa bacteriocins. A three-stranded
β-sheet structure can be found at the N-terminus, this is often
stabilized by a conserved disulphide bridge formed between
two cysteine residues at the N-terminus. Because aquaticin
has only a single cysteine residue and acidicin completely
lacks cysteine residues these bacteriocins would be unable to
produce the conserved disulphide bond. The C-terminus is less
conserved and can be composed of one or two α-helices and an
elongated C-terminal tail which can fold back on the α-helix,
forming a hairpin-like structure. A C-terminal disulphide bond
can stabilize this hairpin structure in certain bacteriocins and
pediocin 20336a, rennicin A, rennicin B, hordeiocin, agilicin
and ruminicin all have the ability to form this disulphide bond
(Fimland et al., 2005).
The N-terminal “YGNGV/L” region is highly conserved in
these peptides, interestingly agilicin is the only such bacteriocin
where the valine or leucine residue in this sequence has
been replaced by an isoleucine. These peptides also contain
a conserved hinge region (VD/NWGXA) which separates the
N-terminal β sheet configuration from the C-terminal α helix
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TABLE 3 | Bacteriocin Activity (BU/ml) vs. L. innocua DPC3572.
E. coli Tuner (DE3) L. paracasei NFBC338
Pediocin PA-1 (PedA) + ++
Rennicin A (RenA) + +
Ruminicin (Rum) +++ +++
Agilicin (Agl) ++ ++
Aquaticin (Aqu) – –
Rennicin B (RenB) – +
Acidicin (Acd) – –
Pediocin 20336a (Ped20336) + +
Futcin (Fut) + –
Hordeiocin (Hrd) +++ ++
Penocin A (PenA) ++ +
Bacteriocin units per ml (BU/ml) were calculated as the inverse of the highest dilution
of bacterial supernatant showing activity against L. innocua DPC3572 in a well diffusion
assay. + = 0 – 160 BU/ml, ++ = 320 – 2560 BU/ml, +++ = 5120 – 10240 BU/ml.
(Uteng et al., 2003). Acidicin contains a valine to isoleucine
substitution in this motif, a modification only previously seen in
lactococcin MMFII (Ferchichi et al., 2001).
DISCUSSION
Due to the growing availability of genomic data and the
improvement of software a growing number of novel bacteriocins
are being identified (Letzel et al., 2014; Zhao and Kuipers,
2016). There continues however, to be a disconnect between
the identification of these genes and the actual production of
these bacteriocins in vitro. Whilst metagenomic data provides
the ability to detect these genes, this is often not correlated to
the isolation and characterization of the producing strain. Thus,
whilst bacteriocin genes are being discovered at a much greater
rate frommetagenomic data, the isolation of these antimicrobials
themselves has proved more difficult.
One method to bridge the gap between the discovery
of bacteriocin genes and their in vitro production is to
heterologously express these genes in a new host. This could
prove particularly valuable for strains that are non-culturable or
that are extremely difficult to grow in the laboratory. Developing
and optimizing cloning techniques for individual bacteriocins
requires time, which can make it a laborious task when working
with a large number of potential bacteriocin genes identified in a
genomic screen. The methods used by Mesa-Pereira et al. (2017)
and in this study provide a rapid mechanism to express non-
lantibiotic bacteriocins such as class IIa bacteriocins and class
IId bacteriocins. It has been determined that the presence of
the bacteriocin structural gene and the bacteriocin transporter is
sufficient to express these bacteriocins using this system (Mesa-
Pereira et al., 2017). This provides a quick and easy method to
produce such bacteriocins, even if the original operons identified
are incomplete. Using this method, it was possible to express
novel bacteriocins identified from in silico screening of the
Lactobacillus Genus Complex, despite many of these lacking
the obligatory genes required for bacteriocin production by the
parent strains. It is unclear as to why such strains encode intact
bacteriocin and immunity genes whilst lacking the machinery
needed to actually produce and secrete these antimicrobials.
One potential explanation for this is that these strains may
have maintained the bacteriocin immunity gene under selective
pressures and that the neighboring small bacteriocin encoding
gene may also have been maintained whilst the larger transport
machinery was lost.
The bacteriocin expression system used is based on the
pediocin PA-1 operon, using the associated transporter PedD
to transport the expressed bacteriocin from the cell. Each of
the ten bacteriocins described here was cloned in an E. coli
heterologous host alongside this transporter using both its native
leader sequence and as a fusion containing the pediocin PA-1
leader as opposed to its own. Of the ten bacteriocins studied
here, nine were novel. The bacteriocins varied from 93.2% to
29.5% amino acid identity to pediocin PA-1. Nine of the ten
bacteriocins displayed antimicrobial activity (aquaticin activity
was not seen and the peptide was not identified after purification
and MALDI-TOF mass spectrometry); the production of these
bacteriocins shows the flexibility in the PedD transporter and
its ability to secrete several bacteriocins. Production levels of
these bacteriocins in an E. coli host was greater when they were
expressed with the pediocin PA-1 leader sequence rather than
their own, this is not surprising given that PedD has evolved to
cleave the pediocin PA-1 leader. Four bacteriocins were produced
and secreted using their native leader which reflects a degree of
redundancy in the specificity of the cleavage domain in the PedD
transporter.
The bacteriocins produced displayed a varying spectrum
of activity despite all belonging to the class IIa bacteriocins.
Pediocin PA-1 is an important commercial additive used in
food production in the form of powdered fermentates such as
ALTA R© 2351 (Kerry Bioscience) for the inhibition of Listeria
species as well as other food spoilage and pathogenic bacteria.
The discovery of novel bacteriocins here with a greater inhibitory
range indicates that alternative bacteriocins may prove to be
more effective additives in food; it also opens up the possibility
for extending the use of these bacteriocins for alternative
applications such as potential therapeutic uses. Further studies
into the effect the structure of these bacteriocins can have
on bacteriocin activity may also allow for targeted peptide
engineering of these bacteriocins to improve activity and extend
their range of inhibition in the future.
The structure of these bacteriocins can be affected by
differences in sequences of these peptides. The N-terminal β-
sheet structure of these bacteriocins can be stabilized by the
presence of a disulphide bridge, aquaticin and acidicin, however,
lack the ability to form such a bond. Sit et al. (2012) previously
found that this disulphide bridge can be removed from class IIa
bacteriocins; this reduces but does not eliminate the peptides’
inhibitory activity. This may explain the lower levels of activity
seen for aquaticin and acidicin. The hydrophobic/amphiphilic C-
terminus of these peptides is less conserved than the N-terminus
and is involved in membrane insertion which results in pore
formation thus killing the target cell and also determines the
spectrum of activity of the bacteriocins (Johnsen et al., 2005). The
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C-terminus is composed of an α-helix followed by a C-terminal
tail which forms a hairpin and folds back upon the α-helix.
This motif can be stabilized by the presence of a C-terminal
disulphide bridge which makes the structure less flexible. Class
IIa bacteriocins lacking this second disulphide bridge tend to be
more heat sensitive and can undergo unfolding, making them
less active at 37◦C (Kaur et al., 2004). Acidicin, futcin, aquaticin
and penocin A all lack the ability to form this disulphide bridge,
which may explain the lower levels of activity seen for these
bacteriocins as the majority of the indicator organisms used
here are grown at 37◦C. In certain bacteriocins, which lack the
ability to form this disulphide bridge, the interaction between
tryptophan residues found just after the hinge region and at
the C-terminus can stabilize the hairpin fold (Fimland et al.,
2002). Penocin A and aquaticin both have terminal tryptophan
residues which would compensate for an absent disulphide
bond. Futcin has a tryptophan residue at position 33 in the
mature peptide; however this is not predicted to be involved in
the stabilization of the hairpin fold; acidicin lacks a stabilizing
terminal tryptophan residue altogether. This may suggest that
such an extended hairpin structure does not form in these
bacteriocins. Structural differences between these bacteriocins
may not only affect their inhibitory activity but alsomay affect the
ability of the pediocin transporter to secrete these bacteriocins.
The bacteriocins which display the greatest divergence form
pediocin PA-1 were, however, shown to be secreted here
indicating a level of redundancy in the transporter which may
extend to the production of other unmodified bacteriocins. This
potential extension of the classes of bacteriocins secreted by this
system is supported by the activity of the transported EnkT from
E. faecium NKR-5-3 which is involved in the transport of a class
IIa bacteriocin, two peptides of a class IIb bacteriocin and also
an inducer peptide (Sushida et al., 2018). This emphasizes the
potential flexibility of these bacteriocin ABC transporters.
The novel bacteriocins described here cluster into different
groups upon alignment. Pediocin, pediocin 20336a, rennicin A
and rennicin B display between 84% and 93% homology to each
other. Despite being 90.9% identical to pediocin PA-1, rennicin
B did not display activity in the crude supernatant from the
E. coli heterologous host; it did however display equal levels of
activity compared to rennicin A when expressed in L. paracasei
NFBC338. Two amino acid substitutions in rennicin B may
explain this as they occur in important structural regions for
the bacteriocin. The Gly29-Ser29 substitution is found in the C-
terminal α-helix of the peptide which is involved in membrane
insertion. The substitution of a non-polar amino acid for a
larger polar one here may affect the formation of the helix and
membrane insertion. A Gly36-Ser36 substitution occurs in a
double glycine motif which follows the α-helix. This motif may
provide the flexibility for the C-terminal tail to fold back upon
the helix (Fimland et al., 2002), this flexibility may be lost due to
the substitution with a larger serine residue.
Hordeiocin, agilicin, futcin and ruminicin to a lesser extent,
also cluster together, displaying between 60% and 76% amino
acid identity. Hordeiocin, agilicin and ruminicin all display a
relatively broad spectrum of activity (inhibiting between 18 and
14 strains), whilst futcin is more narrow spectrum (inhibiting
nine strains) which again may be due to a lack of a C-terminal
stabilizing disulphide bridge. Penocin A, acidicin and aquaticin
lack a high degree of similarity to each other and the other
bacteriocins produced.
Through analysis of the data from previous in silico
bacteriocin screens there is the potential to use these cloning
systems to a far greater extent to increase the current repertoire
of unmodified class II bacteriocins. Whilst this study focuses
on the Lactobacillus Genus Complex, numerous other studies
have analyzed large amounts of genomic data from other sources
to identify novel bacteriocins. Zheng et al. (2015) screened 700
shotgun metagenomic datasets from the Human Microbiome
Project for the presence of bacteriocin operons. Of the 4875
putative bacteriocin genes found here, there were 3048 potential
class II bacteriocins including 50 class IIa pediocin homologs,
all of which represent potential candidates for use in this
expression system. Similarly Alvarez-Sieiro et al. (2016) screened
238 genomes of lactic acid bacteria using BAGEL3, from this
they identified 785 putative bacteriocin genes of which 514
encoded potential unmodified bacteriocin genes containing 31
class IIa homologs. Other such in silico screening studies have
identified 209 further unmodified bacteriocin genes (Kjos et al.,
2011; Azevedo et al., 2015; Walsh et al., 2015; Liu et al., 2016).
While duplications and false positives are likely to occur in these
datasets, even if a small proportion of these genes can be analyzed
using this expression system it represents a significant extension
of the class II bacteriocins.
Thus whilst in silico genomic studies can lead to the
identification of bacteriocins, often this research is not carried
forward leading to the characterization of these antimicrobials.
The simple system used here outlines how bacteriocin genes
identified through in silico screening of the Lactobacillus Genus
Complex could easily be heterologously expressed. Bacteriocins
which otherwise would not have been produced by the original
strain due to tight regulation of the operon or loss of necessary
genes were able to be produced and studied. Ten class IIa
bacteriocins were studied here, nine of which were novel.
Nine of these bacteriocins were produced and secreted by
the PedD transporter, despite showing less than 30% identity
to pediocin PA-1, which reflects the permissiveness of the
transporter in secreting these peptides. These novel bacteriocins
notably extend the group of class IIa bacteriocins, however
these would likely not have been produced and analyzed if
not for the expression systems used here. This has allowed
us to reincarnate these bacteriocin relics, and provides the
capacity to identify and produce a vast range of novel
bacteriocins identified by other in silico screens which may
otherwise be destined to remain uncharacterized in their genomic
graveyard.
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